Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.

Rodon P, Hulin C, Pegourie B, Tiab M, Anglaret B, Benboubker L, Jardel H, Decaux O, Kolb B, Roussel M, Garderet L, Leleu X, Fitoussi O, Chaleteix C, Casassus P, Lenain P, Royer B, Banos A, Benramdane R, Cony-Makhoul P, Dib M, Fontan J, Stoppa AM, Traullé C, Vilque JP, Pétillon MO, Mathiot C, Dejoie T, Avet-Loiseau H, Moreau P.

Haematologica. 2015 Feb;100(2):e56-9. doi: 10.3324/haematol.2014.110890. Epub 2014 Nov 14. No abstract available.

2.

Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.

Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T, Gastinne T, Delaunay J, Blin N, Mahé B, Dubruille V, Augeul-Meunier K, Peterlin P, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Mohty M, Moreau P, Le Gouill S.

Ann Oncol. 2015 Feb;26(2):386-92. doi: 10.1093/annonc/mdu515. Epub 2014 Nov 12.

PMID:
25392158
3.

Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study.

Néel A, Henry B, Barbarot S, Masseau A, Perrin F, Bernier C, Kyndt X, Puechal X, Weiller PJ, Decaux O, Ninet J, Hot A, Aouba A, Astudillo L, Berthelot JM, Bonnet F, Brisseau JM, Cador B, Closs-Prophette F, Dejoie T, de Korwin JD, Dhote R, Fior R, Grosbois B, Hachulla E, Hatron PY, Jardel H, Launay D, Lorleac'h A, Pottier P, Moulis G, Serratrice J, Smail A, Hamidou M.

Autoimmun Rev. 2014 Oct;13(10):1035-41. doi: 10.1016/j.autrev.2014.08.031. Epub 2014 Aug 23.

PMID:
25220180
4.

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team.

N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.

5.

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.

Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, Maurier F, Jouneau S, Bienvenu B, Puéchal X, Aumaître O, Le Guenno G, Le Quellec A, Cevallos R, Fain O, Godeau B, Seror R, Dunogué B, Mahr A, Guilpain P, Cohen P, Aouba A, Mouthon L, Guillevin L; French Vasculitis Study Group.

Arthritis Rheum. 2013 Jan;65(1):270-81. doi: 10.1002/art.37721.

6.

[Vitamin D supplementation: A iatrogenic hypercalcemia concerning an HIV-infected patient with disseminated tuberculosis].

Lescoat A, Poinsignon Y, Dos Santos A, Cano Y, Floc'h F, Jardel H.

Presse Med. 2012 Dec;41(12 Pt 1):1299-301. doi: 10.1016/j.lpm.2012.05.028. Epub 2012 Sep 14. French. No abstract available.

PMID:
22981408
7.

Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.

Thiébaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, Chêne G, Collin G, Matheron S, Descamps D, Brun-Vézinet F; French ANRS HIV-2 CO5 Cohort.

Clin Infect Dis. 2012 Nov 15;55(10):1417-25. doi: 10.1093/cid/cis708. Epub 2012 Aug 20.

8.

Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.

Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A; French Group of Familial Myeloproliferative Disorders.

Blood Cells Mol Dis. 2012 Oct 15-Dec 15;49(3-4):170-6. Epub 2012 Jul 19.

PMID:
22818858
9.

Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL; IFM Investigators.

N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.

10.

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.

Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Voillat L, Moreau P, Berthou C, Stoppa AM, Maloisel F, Rodon P, Dib M, Pegourie B, Casassus P, Slama B, Damaj G, Zerbib R, Harousseau JL, Mohty M, Facon T; Intergroupe Francophone du Myélome (IFM).

Eur J Haematol. 2012 Mar;88(3):249-59. doi: 10.1111/j.1600-0609.2011.01729.x. Epub 2012 Jan 4.

PMID:
22023551
11.

X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI.

Ghosn J, Galimand J, Raymond S, Meyer L, Deveau C, Goujard C, Izopet J, Rouzioux C, Chaix ML; ANRS CO 06 PRIMO cohort.

PLoS One. 2011;6(8):e23301. doi: 10.1371/journal.pone.0023301. Epub 2011 Aug 24.

12.

Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience.

Avet-Loiseau H, Roussel M, Campion L, Leleu X, Marit G, Jardel H, Dib M, Decaux O, Lamy T, Tiab M, Cony-Makhoul P, Banos A, Lepeu G, Lifermann F, Macro M, Kolb B, Hulin C, Caillot D, Traulle C, Mathiot C, Royer B.

Leukemia. 2012 Jan;26(1):158-9. doi: 10.1038/leu.2011.176. Epub 2011 Jul 29. No abstract available.

PMID:
21799511
13.

[Pulmonary and cutaneous lesions].

Hudier L, Poinsignon Y, Dos Santos A, Lesourd A, Pouedras P, Godmer P, Jardel H.

Rev Med Interne. 2011 Nov;32(11):706-7. doi: 10.1016/j.revmed.2010.12.007. Epub 2011 Jan 20. French. No abstract available.

PMID:
21255879
14.

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).

N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095.

15.

Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients.

Roland V, Bodet-Milin C, Moreau A, Gastinne T, Mahé B, Dubruille V, Maisonneuve H, Juge-Morineau N, Moreau P, Jardel H, Planche L, Mohty M, Moreau P, Harousseau JL, Kraeber-Bodéré F, Le Gouill S.

Bone Marrow Transplant. 2011 Mar;46(3):393-9. doi: 10.1038/bmt.2010.130. Epub 2010 May 31.

PMID:
20577223
16.

Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.

Bodet-Milin C, Touzeau C, Leux C, Sahin M, Moreau A, Maisonneuve H, Morineau N, Jardel H, Moreau P, Gallazini-Crépin C, Gries P, Gressin R, Harousseau JL, Mohty M, Moreau P, Kraeber-Bodere F, Le Gouill S.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1633-42. doi: 10.1007/s00259-010-1469-2. Epub 2010 Apr 29.

PMID:
20428863
17.

Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.

Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D; ANRS AC11 Resistance Group; Cohort PRIMO ANRS CO 6; FHDH ANRS CO4 Study Groups.

AIDS. 2009 Mar 27;23(6):717-24. doi: 10.1097/QAD.0b013e328326ca77.

PMID:
19279445
18.
19.

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).

J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20.

20.

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.

Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H; Intergroupe Francophone du Myélome.

Lancet. 2007 Oct 6;370(9594):1209-18.

PMID:
17920916
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk